Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study

Jing Wang; Jie Huang; Shuang Yang; Chang Cui; Ling Ye; Sai-Ying Wang; Guo-Ping Yang; Qi Pei

doi:10.2147/DDDT.S224553

Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study

Drug Des Devel Ther. 2019 Dec 6:13:4135-4144. doi: 10.2147/DDDT.S224553. eCollection 2019.

Authors

Jing Wang^#^{1

2}, Jie Huang^#^{1

3}, Shuang Yang^{1

3}, Chang Cui^{1

3}, Ling Ye^{1

3}, Sai-Ying Wang⁴, Guo-Ping Yang^{1

3}, Qi Pei^{1

2}

Affiliations

¹ Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People's Republic of China.
² Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People's Republic of China.
³ Clinical Trails Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People's Republic of China.
⁴ Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People's Republic of China.

^# Contributed equally.

Abstract

Purpose: To assess the pharmacokinetics and safety of pure S-ketamine (esketamine) in Chinese patients undergoing painless gastroscopy and evaluate the potential advantage of esketamine in clinical treatment compared with racemate ketamine hydrochloride injection.

Patients and methods: A randomized, open-label, parallel-controlled, Phase I study was performed with 32 patients undergoing painless gastroscopy. Patients received a single dose of esketamine (0.5 mg/kg) or racemic ketamine (1 mg/kg, esketamine:R-ketamine=1:1), injected in 10 s. Blood samples were collected for pharmacokinetic analysis. The concentrations of esketamine, R-ketamine, S-norketamine, and R-norketamine were measured with a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method.

Results: After administering a single dose of esketamine and racemate ketamine, the pharmacokinetics parameters of esketamine and S-norketamine are both similar in treatment groups. The clearance of esketamine in two groups was 18.1±3.2 and 18.4±3.4 mL/min•kg, respectively. However, in the ketamine group, esketamine has a larger clearance than R-ketamine (18.4±3.4 mL/min·kg vs 15.8±3.1 mL/min·kg, P<0.001). Further analysis showed that gender did not affect the pharmacokinetics of esketamine and racemate ketamine. Regarding the safety of esketamine and racemate ketamine, no serious adverse events were observed during treatment, and the incidences of adverse events were 75.0% (esketamine) and 87.5% (racemate ketamine). The main adverse reactions were dizziness, agitation, nausea, vomiting, headache, and fatigue. However, compared with racemic ketamine, esketamine offers a shorter recovery time (9 mins vs. 13 mins, P<0.05) and orientation recovery time (11.5 mins vs. 17 mins, P<0.05) after short anesthesia.

Conclusion: Esketamine administration as a single dose of 0.5 mg/kg was generally safe and tolerated in patients undergoing painless gastroscopy. In terms of anesthesia, a relatively small dose of esketamine can be used instead of racemate ketamine for routine treatment without consideration of gender differences.

Keywords: Chinese patients; anesthesia; esketamine; pharmacokinetics; racemate ketamine.

Publication types

Clinical Trial, Phase I
Comparative Study
Randomized Controlled Trial

MeSH terms

Adult
Anesthesia
Antidepressive Agents / administration & dosage
Antidepressive Agents / blood
Antidepressive Agents / pharmacokinetics*
China
Dose-Response Relationship, Drug
Female
Gastroscopy*
Humans
Ketamine / administration & dosage
Ketamine / blood
Ketamine / pharmacokinetics*
Male
Molecular Structure
Structure-Activity Relationship
Young Adult

Substances

Antidepressive Agents
Esketamine
Ketamine